Correct - current stage of 12cq development is focusing on Single and few Qubit Control.
This is by no means an easy feat - keep in mind no one in the world has done what they are doing and they are pushing todays technological boundaries - it's a world first so it's going to take time to get this right. When they have completed this section then it will be another Major Milestone met towards commercialization. Defiantly and long term hold to realize greater value here, but traders have done very well in the past here.
Expecting Patent news sometime next week if the dossier site is anything to go by. I would be expecting large volumes and trades on Patent news.. but there is so much more in the pipeline than just the patents being approved - just have to exercise patience with this stock and I'm of the strong believe it will certainly off in the future.
Last announcement regarding 12cq build was 12 July 2021
• Significant 12CQ chip development progress made with the first quantum information signals detected that indicate on-chip qubit control. • Quantum control of qubits integrated with miniaturized chip devices under various environment and system conditions is required for 12CQ chip operation. • The progress made is a major technological feat and represents a crucial step towards realizing 12CQ as a viable chip-based qubit architecture. • Archer is advancing its world-first technology development with an immediate focus on achieving qubit control. • Archer is the only ASX listed company and one of a few players in the world developing a qubit processor chip in the quantum computing industry.
Regarding the A1 Bio Chip - current besides on chip testing I believe they are focusing on increasing the sensor count ie... increasing the sensors per 1cm2 ( currently 1 million and working on 10's of Millions -150 nm to Sub 10 Nanometer fabrication ) This is all to do with improving sensitivity - the greater the sensor count the greater the detecting sensitivity!
"Archer Materials Limited (“Archer”, the “Company”, “ASX:AXE”)is pleased to inform shareholders that the Company has commenced development towards a key technological milestone of achieving sub-10 nanometre biochip components. Archer staff are now directly operating the world-class lithography systems and instrumentation required to achieve this milestone in a research and prototype foundry. Sub-10 nanometres (nm)represents global best-in-class in the semiconductor industry Miniaturization to below 10 nm is required for the successful development of Archer’s biochip (1 nanometre is a billionth of a meter). The Company recently made a step-change in its biotech development by miniaturising key biosensor nanoscale chip formats on silicon wafers(ASX ann. 22 Mar 2021) with feature sizes of 100-150 nm from centimeter (“cm”)size (ASX ann. 31 Aug 2020) (i.e.1 million+ sensor components in the same cm2area). Company staff are now trained to directly utilize the Elionix ELS-125 electron-beam lithography system and associated instrumentation (Image 1) (“E-beam”), in Sydney, Australia. Archer aims touse the E-beam tocreatesub-10 nm features for its prototype biochip devices. In doing so, the Company would overcome significant barriers to entry, including pattern design and process optimization, for on-chip fabrication of biosensor components. Commenting on Archer’s nanofabrication development, Archer CEO Dr Mohammad Choucair said“ Archer has progressed to one of the most advanced forms of nanofabrication after recently translating biosensor components onto silicon wafers. We are expanding on this strength with in-house capability to build a robust biochip IP portfolio. This is key to Archer’s long-term growth, and near-term speed of execution in its deep tech development”. “Best-in-class capabilities in nanofabrication is a global competitive advantage in the multibillion-dollar point of care medical diagnostics industry. One of the reasons why there are few companies in the world developing and commercializing biochips is because it’s difficult to achieve precision engineering at the nano scale”.
Interesting strong finish to last week so will see how this continues next week. Looking forward to it!
Stay safe Tonza
AXE Price at posting:
$1.92 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)